International Journal of Cardiology
Volume 131, Issue 2 , Pages 168-179 , 9 January 2009

Aetiology and risk factors of peripartum cardiomyopathy: A systematic review

  • Ntobeko B.A. Ntusi
    • ,
  • Bongani M. Mayosi

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Medicine, J Floor Old Main Building, Groote Schuur Hospital, Observatory, 7925, Cape Town, South Africa. Tel.: +27 21 406 6200; fax: +27 21 448 6815.

Received 24 September 2007 ,Revised 29 May 2008 ,Accepted 28 June 2008.

References 

  1. Ritchie C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases in the heart. Edinburgh Med Surg J. 1849;2:333
  2. Sakakibara S, Sekiguchi M, Konno S, Kusumoto M. Idiopathic postpartum cardiomyopathy: report of a case with special reference to its ultrastructural changes in the myocardium as studies by endomyocardial biopsy. Am Heart J. 1970;80:385–395
  3. Hull E, Hafkesbring E. “Toxic” postpartal heart disease. N Orleans Med Surg J. 1937;89:550–557
  4. Gouley BA, McMillan TM, Bellet S. Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci. 1937;19:185–199
  5. Pearson GD, Veille JC, Rahimtoola S, Hsia J, Oakley CM, Hosenpud JD, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop Recommendations and Review. JAMA. 2000;283:1183–1188
  6. Reimold SC, Rutherford JD. Peripartum cardiomyopathy. N Engl J Med. 2001;344:1629–1630
  7. Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005;112:3577–3583
  8. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. The Lancet. 2006;368:687–693
  9. Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit Care Med. 2005;33:S340–S346
  10. Ro A, Frishman WH. Peripartum cardiomyopathy. Cardiol Rev. 2006;14:35–42
  11. Aboud J, Murad A, Chen-Scarabelli C, et al. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007;118:295–303
  12. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600
  13. Leinwand LA. Molecular events underlying pregnancy-induced cardiomyopathy. Cell. 2007;128:437–438
  14. Elkayam U, Akhter MW, Singh HS, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050–2055
  15. Ribner SH, Silverman RI. Peripartal cardiomyopathy. In:  Elkayam U,  Gleicher N editor. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. 2nd. New York: Alan R Liss; 1990;p. 115–127
  16. Stuart KL. Cardiomyopathy of pregnancy and the puerperium. Q J Med. 1968;37:463–477
  17. Cunningham FG, Pritchard JA, Hankins GD, Anderson PL, Lucas MJ, Armstrong KF. Peripartum heart failure: idiopathic cardiomyopathy or compounding cardiovascular events?. Obstet Gynecol. 1986;67:157–168
  18. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989;256:1060–1065
  19. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80:1602–1606
  20. Kuhl U, Pauschinger M, Seeberg B, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112:1965–1970
  21. Krause PJ, Ingardia CJ, Pontius LT, Malech HL, LoBello TM, Maderazo EG. Host defense during pregnancy: neutrophil chemotaxis and adherence. Am J Obstet Gynecol. 1987;157:274–280
  22. Farber PA, Glasgow LA. Viral myocarditis during pregnancy: encephalomyocarditis virus infection in mice. Am Heart J. 1970;80:96–102
  23. Lyden DC, Huber SA. Aggravation of coxsackievirus, group B, type 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animals treated with progesterone. Cell Immunol. 1984;87:462–472
  24. Melvin KR, Richardson PJ, Olsen EG, Daly K, Jackson G. Peripartum cardiomyopathy due to myocarditis. N Engl J Med. 1982;307:731–734
  25. Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease: an endomyocardial biopsy study. Br Heart J. 1986;56:285–291
  26. O'Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon PJ, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986;8:52–56
  27. Midei M, DeMent S, Feldman A, Hutchins G, Baughman K. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81:922–928
  28. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–1084
  29. Cenac A, Gaultier Y, Devillechabrolle A, Moulias R. Enterovirus infection in peripartum cardiomyopathy. The Lancet. 1988;2:968–969
  30. Cenac A, Djibo A, Chaigneau C, Velmans N, Orfila J. Are anti-Chlamydia pneumoniae antibodies prognosis indicators for peripartum cardiomyopathy?. J Cardiovasc Risk. 2003;10:195–199
  31. Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol. 1994;74:474–477
  32. Bultmann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005;193:363–365
  33. Cenac A, Beaufils H, Soumana I, Vetter JM, Devillechabrolle A, Moulias R. Absence of humoral autoimmunity in peripartum cardiomyopathy. A comparative study in Niger. Int J Cardiol. 1990;26:49–52
  34. Warriach RS, Sliwa K, Damasceno A, et al. Impact of pregnancy-related heart failure on humoral immunity: clinical relevance of G3-subclass immunoglobulins in peripartum cradiomyopathy. Am Heart J. 2005;150:263–269
  35. Jahns R, Boivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429
  36. Freedman NJ, Lefkowitz RJ. Anti-β1-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;113:1379–1382
  37. Bianchi D, Flint A, Pizzimenti M, Knoll J, Latt S. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. PNAS. 1990;87:3279–3283
  38. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. PNAS. 1996;93:705–708
  39. Ansari AA, Fett JD, Carraway RD, et al. Autoimmune mechanisms as the basis of for human peripartum cardiomyopathy. Clin Rev Allergy Immunol. 2002;23:301–324
  40. Artlett CM, Smith B, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Eng J Med. 1998;338:1186–1191
  41. Sundstrom JB, Fett JD, Carraway RD, Ansari AA. Is peripartum cardiomyopathy an organ-specific autoimmune disease?. Autoimmun Rev. 2002;1:73–77
  42. Fett JD, Dowell DL, Carraway RD, Sundstrom JB, Ansari AA. One hundred cases of peripartum cardiomyopathy… and counting: what is going on?. Int J Cardiol. 2004;97:571–573
  43. Geva T, Mauer MB, Striker L, Kirshon B, Pivarnik JM. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J. 1997;133:53–59
  44. Capeless EL, Clapp JF. When do cardiovascular parameters return to their preconception values?. Am J Obstet Gynecol. 1991;165:883–886
  45. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer MRML. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol. 1997;176:189–195
  46. MacLellan WR, Schneider MD. Death by design: programmed cell death in cardiovascular biology and disease. Circ Res. 1997;81:137–144
  47. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest. 2003;111:1497–1504
  48. Narula J, Kolodgie FD, Virmani R. Apoptosis and cardiomyopathy. Curr Opinion Cardiol. 2000;15:183–188
  49. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC, et al. In: Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. 8:2002;p. 725–730
  50. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, et al. Enhanced G alpha q signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. PNAS. 1998;95:10140–10145
  51. Hayakawa Y, Chandra M, Miao W, Shirani J, Brown JH, Dorn GW, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of G{alpha}q transgenic mice. Circulation. 2003;108:3036–3041
  52. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35(3):701–705
  53. Packer M. Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?. Circulation. 1995;92:1379–1382
  54. Drexler H. Changes in the peripheral circulation in heart failure. Curr Opin Cardiol. 1995;10:268–273
  55. Mann DL. Stress activated cytokines and the heart: from adaptation to maladaptation. Cytokine Growth Factor Rev. 1996;7:341–354
  56. Paulus WJ. How are cytokines activated in heart failure?. Eur J Heart Fail. 1999;100:999–1008
  57. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-{alpha}. Circ Res. 1997;81:627–635
  58. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-{alpha} promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391
  59. Mann DL. Stress activated cytokines and the heart: from adaptation to maladaptation. Cytokine Growth Factor Rev. 1996;7:341–354
  60. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748–755
  61. Damas JK, Gullestad L, Aukrust P. Cytokines as new treatment targets in chronic heart failure. Curr Control Trials Cardiovasc Med. 2001;2:271–277
  62. Satoh M, Nakamura M, Akatsu T, et al. C-reactive protein co-expresses with tumour necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur Heart J. 2005;7:748–754
  63. Walsh JJ, Burch GE, Black WC, Ferrans VJ, Hibbs RG. Idiopathic myocardiopathy of the puerperium (postpartal heart disease). Circulation. 1965;32:19–31
  64. Fillmore SJ, Parry EO. The evolution of peripartal heart failure in Zaria. Circulation. 1977;56:1058–1061
  65. Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol. 2002;86:311–316
  66. Cenac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol. 1992;36:57–59
  67. Pierce JA, Price BO, Joyce JW. Familial occurrence of postpartal heart failure. Arch Intern Med. 1963;111:151–155
  68. Massad LS, Reiss CK, Mutch DG, Haskel EJ. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol. 1993;81:886–888
  69. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J. 1995;129:421–422
  70. Voss EG, Reddy CV, Detrano R, Virmani R, Zabriskie JB, Fotino M. Familial dilated cardiomyopathy. Am J Cardiol. 1984;54:456–457
  71. Fett JD, Sundstrom BJ, Etta King M, Ansari AA. Mother–daughter peripartum cardiomyopathy. Int J Cardiol. 2002;86:331–332
  72. Kühl U, Pauschinger M, Michel Noutsias M, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111:887–893
  73. Horwitz MS, Knudsen M, Fine C, et al. Transforming growth factor-beta inhibits cocksackievirus mediated autoimmune myocarditis. Viral Immunol. 2006;19:722–733
  74. Lang C, Sauter M, Szalay G, et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enetrovirus myocarditis. J Mol Med. 2007;86:49–60
  75. Glück B, Schmidtke M, Merkle I, et al. Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol. 2001;33:1615–1626
  76. Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006;27:441–446
  77. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173:219–238
  78. Bryant EE, Douglas BH, Ashburn AD. Circulatory changes following prolactin administration. Am J Obstet Gynecol. 1973;115:53–57
  79. Kothari SS. Aetiopathogenesis of peripartum cardiomyopathy: prolactin–selenium interaction?. Int J Cardiol. 1977;60:111–114
  80. Iffy L, TenHove W, Frisoli G. Acute myocardial infarction in the puerperium in patients receiving bromocriptine. Am J Obstet Gynecol. 1986;155:371–372
  81. Ruch A, Duhring JL. Postpartum myocardial infarction in a patient receiving bromocriptine. Obstet Gynecol. 1989;74:448–451
  82. Dargaud Y, Pariset C, Pinede L, et al. Multiple arterial thromboses in a patient with primary antiphospholipid syndrome receiving bromocriptine therapy. Lupus. 2004;13:957–960
  83. Hopp L, Bunyad H, Iffy L. Myocardial infarction postpartum in patients taking bromocriptine for the prevention of breast engorgement. Int J Cardiol. 1996;57:227–232
  84. Hopp L, Weisse AB, Iffy L. Acute myocardial infarction in a healthy mother using bromocriptine for milk suppression. Can J Cardiol. 1996;12:415–418
  85. Fett J. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol (in press).
  86. Musser JH, Sodeman WA, Turner RH. Heart failure or acute nephritis with onset about 3 weeks after delivery. Ann Int Med. 1938;12:739–753
  87. Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J. 1995;130:860–870
  88. Coulson C, Thorp JM, Mayer D, Cefalo R. Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol. 1996;87:610–612
  89. Wittstein IS, Thiemann DR, Lima JAC, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539–548
  90. Lee RV. Peripartum cardiomyopathy: time for another look?. J Obstet Gynaecol. 2007;27:1–2
  91. Mendelson MA, Chandler J. Postpartum cardiomyopathy associated with maternal cocaine abuse. Am J Cardiol. 1992;70:1092–1094
  92. Homans DC. Peripartum cardiomyopathy. N Eng J Med. 1985;312:1432–1437
  93. Koide T, Saito Y, Sakemoto T, Murao S. Peripartal cardiomyopathy in Japan: a critical reappraisal of the concept. Jpn Heart J. 1972;13:488–501
  94. Bassett JM, Burks AH, Levine DH, Pinches RA, Visser GH. Maternal and fetal metabolic effects of prolonged ritodrine infusion. Obstet Gynecol. 1985;66:755–761
  95. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol. 1993;168:493–495
  96. Ingemarsson I, Arulkumaran S, Kottegoda SR. Complications of beta-mimetic therapy in preterm labour. Aust N Z J Obstet Gynaecol. 1985;25:182–189
  97. Pisani RJ, Rosenow EC. Pulmonary oedema associated with tocolytic therapy. Ann Intern Med. 1989;110:714–718
  98. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971;44:964–968
  99. Elkayam U, Akhter MW, Singh HS, et al. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol. 1984;148:805–818
  100. Mielniczuk LM, Williams K, Davies DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97:1765–1768
  101. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302–304

☆ The authors of this article are funded in part by research grants from the University of Cape Town, Medical Research Council of South Africa, the National Research Foundation, and the Wellcome Trust (UK).

PII: S0167-5273(08)00824-3

doi: 10.1016/j.ijcard.2008.06.054

International Journal of Cardiology
Volume 131, Issue 2 , Pages 168-179 , 9 January 2009

Article Tools

* Image Usage & Resolution